Insider Selling: Keros Therapeutics (NASDAQ:KROS) Insider Sells $36,714.72 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) insider Lorena Raquel Lerner sold 3,568 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider owned 27,559 shares in the company, valued at approximately $283,582.11. The trade was a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Keros Therapeutics Stock Up 0.7%

NASDAQ:KROS opened at $11.03 on Friday. The company has a market capitalization of $218.72 million, a PE ratio of -2.98 and a beta of 0.99. The stock has a fifty day simple moving average of $10.71 and a 200-day simple moving average of $11.84. Keros Therapeutics, Inc. has a 52-week low of $9.69 and a 52-week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.16 earnings per share for the current year.

Analysts Set New Price Targets

KROS has been the subject of a number of recent research reports. Wells Fargo & Company dropped their price objective on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Keros Therapeutics in a report on Tuesday, August 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Leerink Partners lowered their target price on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday, August 4th. Finally, Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 16th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Hold” and an average price target of $20.50.

Institutional Trading of Keros Therapeutics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in Keros Therapeutics in the second quarter valued at $29,898,000. Vanguard Group Inc. raised its holdings in shares of Keros Therapeutics by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,718,777 shares of the company’s stock worth $43,011,000 after purchasing an additional 87,129 shares during the period. Nantahala Capital Management LLC acquired a new position in shares of Keros Therapeutics in the 2nd quarter valued at about $15,091,483,000. Jacobs Levy Equity Management Inc. grew its holdings in shares of Keros Therapeutics by 26.6% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 768,425 shares of the company’s stock worth $15,645,000 after purchasing an additional 161,336 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after purchasing an additional 205,022 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.